Feasibility and acceptability of a timeline follow-back method to assess opioid use, non-fatal overdose, and substance use disorder treatment

McCann, Nicole C.; McMahan, Vanessa M.; Smith, Rachel; Majeski, Adam; Johns, Sarah L.; Kosakowski, Sarah; Wolfe, Shae; Brennan, Sarah; Robinson, Mackenzie; Coffin, Phillip O.; Walley, Alexander Y.

doi:10.1016/j.addbeh.2023.107873

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Time-Line Follow Back (TLFB) method will be employed at the three- and six-month intervals to quantify self-reported frequency of opioid use and maximum weeks of abstinence. The TLFB is a reliable and valid tool in assessing self-reported drug use and leverages a calendar and significant events to aid participants in recalling their substance use patterns, thereby offering a comprehensive view of consumption trends over time 55 . Perceived stress will be assessed using the perceived stress scale (PSS).…”

Section: Plan For Researchmentioning

confidence: 99%

Opioid use disorder and role of yoga as an adjunct in management (OUDARYAM): Study protocol for a randomized controlled trial

Bhargav,

Holla,

Mahadevan

et al. 2024

Wellcome Open Res

View full text Add to dashboard Cite

Background The proposed research aims to test the effects and mechanisms of a six-month yoga-based intervention as an add-on to standard treatment in opioid use disorder (OUD) by conducting a randomized controlled study with the following primary outcome variables: 1) clinical: abstinence (opioid negative urine test), and reductions in pain and craving, and 2) mechanisms: reward circuit activation in response to opioid visual cue craving paradigm, activation in response to a cognitive control task, and resting state functional connectivity through fMRI, and plasma beta-endorphin levels. Secondary outcome variables are perceived stress, anxiety, sleep quality, cognitive performance, pain threshold, buprenorphine dosage and side effects, withdrawal symptoms, socio-occupational functioning, vedic personality traits, heart rate variability, serum cortisol, and brain GABA levels through magnetic resonance spectroscopy (MRS). Methods In this single-blinded, randomized, controlled, parallel-group superiority trial with 1:1 allocation ratio, 164 patients with OUD availing the outpatient/ inpatient clinical services at a tertiary mental healthcare hospital in India will be enrolled after giving informed consent. Consecutive consenting patients will be randomly allotted to one of the two groups – yoga arm (standard treatment + yoga-based intervention), or waitlist group (standard treatment alone). Allocation concealment will be followed, the clinicians, outcome assessors and data analysts will remain blind to subject-group allocation. A validated and standardized yoga program for OUD will be used as an intervention. Participants in the yoga arm will receive 10 supervised in-person sessions of yoga in the initial two weeks followed by tele-yoga sessions thrice a week for the next 22 weeks. The wait-list control group will continue the standard treatment alone for 24 weeks. Assessments will be done at baseline, two weeks, 12 weeks, and 24 weeks. Data from all randomized subjects will be analysed using intent-to-treat analysis and mixed model multivariate analysis. Dissemination Findings will be disseminated through peer-reviewed publication, conference presentations, and social media. Trial registration number The trial has been registered under Clinical Trials Registry-India with registration number CTRI/2023/03/050737.

show abstract

Section: Plan For Researchmentioning

confidence: 99%

Opioid use disorder and role of yoga as an adjunct in management (OUDARYAM): Study protocol for a randomized controlled trial

Bhargav,

Holla,

Mahadevan

et al. 2024

Wellcome Open Res

View full text Add to dashboard Cite

show abstract

“…Further, increasingly primary care visits are virtual, and urine drug screening may add costs to treatment that patients cannot afford. TLFB could conceivably be used in MBC; for example, feasibility for assessing opioid use by an adaptation of TLFB with 4-monthly visits over 16 months of participation has been recently reported [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus

Rush,

Gore-Langton,

Bart

et al. 2024

Addict Sci Clin Pract

View full text Add to dashboard Cite

Background The prevalence and associated overdose death rates from opioid use disorder (OUD) have dramatically increased in the last decade. Despite more available treatments than 20 years ago, treatment access and high discontinuation rates are challenges, as are personalized medication dosing and making timely treatment changes when treatments fail. In other fields such as depression, brief measures to address these tasks combined with an action plan—so-called measurement-based care (MBC)—have been associated with better outcomes. This workgroup aimed to determine whether brief measures can be identified for using MBC for optimizing dosing or informing treatment decisions in OUD. Methods The National Institute on Drug Abuse Center for the Clinical Trials Network (NIDA CCTN) in 2022 convened a small workgroup to develop consensus about clinically usable measures to improve the quality of treatment delivery with MBC methods for OUD. Two clinical tasks were addressed: (1) to identify the optimal dose of medications for OUD for each patient and (2) to estimate the effectiveness of a treatment for a particular patient once implemented, in a more granular fashion than the binary categories of early or sustained remission or no remission found in The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). Discussion Five parameters were recommended to personalize medication dose adjustment: withdrawal symptoms, opioid use, magnitude (severity and duration) of the subjective effects when opioids are used, craving, and side effects. A brief rating of each OUD-specific parameter to adjust dosing and a global assessment or verbal question for side-effects was viewed as sufficient. Whether these ratings produce better outcomes (e.g., treatment engagement and retention) in practice deserves study. There was consensus that core signs and symptoms of OUD based on some of the 5 DSM-5 domains (e.g., craving, withdrawal) should be the basis for assessing treatment outcome. No existing brief measure was found to meet all the consensus recommendations. Next steps would be to select, adapt or develop de novo items/brief scales to inform clinical decision-making about dose and treatment effectiveness. Psychometric testing, assessment of acceptability and whether the use of such scales produces better symptom control, quality of life (QoL), daily function or better prognosis as compared to treatment as usual deserves investigation.

show abstract

Feasibility and acceptability of a timeline follow-back method to assess opioid use, non-fatal overdose, and substance use disorder treatment

Cited by 2 publications

References 20 publications

Opioid use disorder and role of yoga as an adjunct in management (OUDARYAM): Study protocol for a randomized controlled trial

Opioid use disorder and role of yoga as an adjunct in management (OUDARYAM): Study protocol for a randomized controlled trial

Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus

Contact Info

Product

Resources

About